Detecting Opsoclonus-myoclonus-ataxia syndrome (OMAS): associations of novel eye tracking metrics with structural localizations in the midbrain

检测眼阵挛-肌阵挛-共济失调综合征（OMAS）：新颖的眼动追踪指标与中脑结构定位的关联

• 批准号: 466995
• 负责人: Wu Susana
• 金额: $ 1.27万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-12-01 至 2022-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=466995&lang=en
• 关键词: Autoimmune; Disease Specific Biomarker; Eye-Tracking; Free Viewing; Midbrain; Neurological; Novel; Opsoclonus-Myoclonus-Ataxia Syndrome (Omas); Structural Localizations; Superior Colliculus

Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare but serious inflammatory neurological disorder that typically affects young children and greatly disturbs their quality of life. There are well-established immunotherapies that have shown to be highly

眼阵挛-肌阵挛-共济失调综合征 (OMAS) 是一种罕见但严重的炎症性神经系统疾病，通常影响幼儿并极大地影响他们的生活质量。有一些成熟的免疫疗法已被证明具有很高的疗效